3/1
04:40 am
phat
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why [Yahoo! Finance]
High
Report
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why [Yahoo! Finance]
2/28
09:03 am
phat
Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
High
Report
Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/27
07:03 pm
phat
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses [Yahoo! Finance]
High
Report
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses [Yahoo! Finance]
2/27
10:58 am
phat
Phathom Pharmaceuticals (PHAT) had its price target raised by Guggenheim from $20.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Phathom Pharmaceuticals (PHAT) had its price target raised by Guggenheim from $20.00 to $25.00. They now have a "buy" rating on the stock.
2/26
03:10 pm
phat
Phathom Pharmaceuticals (PHAT) was given a new $28.00 price target by Stifel Nicolaus.
Low
Report
Phathom Pharmaceuticals (PHAT) was given a new $28.00 price target by Stifel Nicolaus.
2/26
07:32 am
phat
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance [Yahoo! Finance]
Low
Report
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance [Yahoo! Finance]
2/26
07:00 am
phat
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Medium
Report
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
2/23
08:25 am
phat
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/23
08:00 am
phat
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
2/17
08:21 am
phat
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 [Yahoo! Finance]
Medium
Report
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 [Yahoo! Finance]
2/17
08:00 am
phat
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
Medium
Report
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
2/5
09:27 am
phat
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 [Yahoo! Finance]
Medium
Report
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 [Yahoo! Finance]
2/5
08:00 am
phat
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Medium
Report
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
1/22
05:41 pm
phat
Gastroesophageal Reflux Disease Market in the US to Show Promising Growth at a CAGR of 6% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
Medium
Report
Gastroesophageal Reflux Disease Market in the US to Show Promising Growth at a CAGR of 6% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
1/14
08:42 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/10
07:02 pm
phat
Should Phathom's US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? [Yahoo! Finance]
Medium
Report
Should Phathom's US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? [Yahoo! Finance]
1/9
07:25 pm
phat
Phathom: Why I'm Not Buying The Dip (Yet) [Seeking Alpha]
Medium
Report
Phathom: Why I'm Not Buying The Dip (Yet) [Seeking Alpha]
1/7
10:33 pm
phat
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
1/7
04:05 pm
phat
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
1/7
04:01 pm
phat
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
High
Report
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
12/13
07:50 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
12/11
05:04 pm
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
12/11
06:29 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Barclays PLC to a "hold" rating.
12/8
06:06 pm
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) was given a new $16.00 price target on by analysts at Barclays PLC.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) was given a new $16.00 price target on by analysts at Barclays PLC.